CHLOROPTIC-P S.O.P.
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CHLOROPTIC-P S.O.P. (CHLOROPTIC-P S.O.P.).
Chloroptic-P S.O.P. contains prednisolone acetate and chloramphenicol. Prednisolone acetate is a corticosteroid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis. Chloramphenicol is a bacteriostatic antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit.
| Metabolism | Prednisolone acetate: primarily hepatic via CYP3A4. Chloramphenicol: primarily hepatic via glucuronidation; also undergoes reduction to inactive metabolites. |
| Excretion | Renal: 50-70% as unchanged drug and metabolites; biliary/fecal: 20-30% as metabolites; small amount via lacrimal drainage after ophthalmic administration. |
| Half-life | Terminal elimination half-life: 2-4 hours (systemic); prolonged to 21-24 hours in severe hepatic impairment. Clinical context: short half-life supports 2-3 times daily dosing. |
| Protein binding | 80-90% bound to plasma proteins (primarily albumin). |
| Volume of Distribution | 0.6-1.2 L/kg; clinical meaning: distributes into total body water, moderate tissue penetration. |
| Bioavailability | Ophthalmic: low systemic bioavailability (approx. 5-10%) due to nasolacrimal drainage and first-pass metabolism; oral: 50-70%. |
| Onset of Action | Ophthalmic (topical): 1-2 hours for intraocular pressure reduction; peak effect at 4-6 hours. |
| Duration of Action | Ophthalmic (topical): 8-12 hours; clinical note: sustained release due to gel matrix (S.O.P.) provides prolonged contact time. |
| Molecular Weight | 430.9 |
Adults: Instill 1/2-inch ribbon into conjunctival sac 3-4 times daily, or more frequently as needed. Not for injection.
| Dosage form | OINTMENT |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No dose adjustment required for hepatic impairment. |
| Pediatric use | Children: Instill 1/2-inch ribbon into conjunctival sac 3-4 times daily. Safety and efficacy not established for use beyond the recommended duration. |
| Geriatric use | Same as adult dose. No specific adjustments required; use caution in patients with glaucoma or other ocular conditions. |
| 1st trimester | Ophthalmic use in pregnancy has not been associated with fetal harm; however, systemic absorption is minimal. Avoid prolonged use. |
| 2nd trimester | Data limited; minimal systemic absorption suggests low risk. Use only if clearly needed. |
| 3rd trimester | Prolonged use near term may theoretically affect neonatal adaptation; generally considered safe with short-term use. |
Clinical note
Comprehensive clinical and safety monograph for CHLOROPTIC-P S.O.P. (CHLOROPTIC-P S.O.P.).
| Placental transfer | Minimal systemic absorption from ophthalmic route; no data on placental transfer, but expected to be negligible due to low dose and ocular administration. |
| Breastfeeding | Minimal systemic absorption after ophthalmic application; very low levels in breast milk. No known adverse effects on nursing infants. Use caution with prolonged treatment. |
■ FDA Black Box Warning
Chloramphenicol is associated with serious and fatal blood dyscrasias (aplastic anemia, hypoplastic anemia, thrombocytopenia, granulocytopenia). It should not be used when less toxic alternatives are available.
| Serious Effects |
Hypersensitivity to any componentBacterial or fungal keratitis (untreated)Perforated globe (relative)
| Precautions | Prolonged use may lead to ocular hypertension/glaucoma, Cataract formation, Secondary ocular infections, Delayed wound healing, Risk of bone marrow suppression with chloramphenicol, Systemic absorption possible, especially with prolonged use |
| Food/Dietary | No known food interactions. Systemic absorption is minimal, so dietary restrictions are not necessary. |
Loading safety data…
| Lactation Rating | L2 (Limited data - probably compatible) |
| Teratogenic Risk | Topical ocular chloramphenicol is minimally absorbed systemically, and no teratogenic effects have been reported in humans. However, based on animal studies and theoretical risk of gray baby syndrome, use in pregnancy should be avoided unless clearly necessary. Risk cannot be ruled out; first-trimester exposure is not associated with specific malformations. |
| Fetal Monitoring | Monitor for signs of systemic toxicity (rare with ophthalmic use): bone marrow suppression (complete blood count), gastrointestinal disturbances. No specific fetal monitoring required unless maternal systemic absorption suspected. |
| Fertility Effects | No known effects on fertility from topical ocular use. Systemic chloramphenicol has no reported impact on human fertility. |
| Clinical Pearls | Chloroptic-P S.O.P. is a combination ophthalmic ointment containing chloramphenicol (antibiotic) and prednisolone (corticosteroid). Use with caution in patients with corneal epithelial defects or viral/fungal infections, as steroids can exacerbate these conditions. Shake well before use to ensure uniform suspension. Avoid prolonged use (>10 days) without re-evaluation due to risk of steroid-induced glaucoma or cataracts. Monitor intraocular pressure if used for extended periods. |
| Patient Advice | Apply a small ribbon (approx. 1 cm) into the conjunctival sac, then close eyes for 1-2 minutes to spread medication. · Avoid touching the tube tip to any surface, including the eye, to prevent contamination. · Do not use this medication for longer than prescribed; prolonged use can increase eye pressure or cause cataracts. · Inform your doctor if you have a history of glaucoma, diabetes, or herpes simplex infection of the eye. · Temporary blurred vision after application is normal; avoid driving or operating machinery until vision clears. |